Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00797316 · ClinicalTrials.gov registry record · Phase 4
Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 532
- Enrollment target
NCT00797316 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 532 participants.
The verdict
NCT00797316, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 532 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) compared to aliskiren monotherapy when given to metabolic syndrome patients with stage 2 systolic hypertension (mean sitting systolic blood pressure \[msSBP\] ≥ 160 mm Hg and \< 200 mm Hg).
Interventions
- DRUG Aliskiren
- DRUG Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 532 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00797316
The ClinicalTrials.gov registry entry for NCT00797316 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 532 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aliskiren is the first listed.
NCT00797316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00797316 about?
NCT00797316 is a clinical study titled "Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension". The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) compared to aliskiren monotherapy when given to metabolic syndrome patients with stage 2 systolic hypertension (mean sitting systolic blood pressure \[msS...
What is the current status of trial NCT00797316?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 532 participants. The study started on 2008-11. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00797316?
The interventions under investigation include: Aliskiren (DRUG), Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00797316?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.